In this second CMEO Snack of the Riding the Waves of Obesity Science series, amylin researcher Matthew R. Hayes, PhD joins moderator Robert F. Kushner, MD for a focused, practical conversation that turns amylin from a half‑remembered footnote into working clinical knowledge; what amylin actually does, how its calcitonin‑receptor/receptor activity-modifying protein (RAMP) biology shapes today’s drug classes, and why its signal complements rather than duplicates glucagon-like peptide-1 (GLP‑1). Designed for physicians, nurse practitioners, physician associates, and pharmacists across obesity medicine, endocrinology, primary care, and cardiometabolic practice, this activity will help you read the emerging science with a sharper eye and be ready for the amylin‑based therapies that may be on the horizon.
- Activities▼
- Education Hubs▼
-
- Alzheimer’s Disease
- Cardiology
- COVID-19
- Dermatology
- Gastroenterology
- Health Access & Social Responsibility
- Hematology
- Immunodeficiency Disorders
- Infectious Disease
- Liver Disease
- Metabolic Diseases Education
- Migraine
- Multiple Sclerosis
- Neuropsychiatric
- Oncology
- Ophthalmology
- Pain Management
- Pediatrics
- Pharmacist Central
- Psoriatic Arthritis
- Rare Diseases
- Respiratory
- Rheumatology
- Sleep Disorders
- Transplant
- Virtual Education
-
- Services▼
- News▼
- ▼